^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Excerpt:
Mirati Therapeutics...announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
Source:
Title:
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
Published date:
10/25/2020
Excerpt:
17% (3/18) of evaluable CRC patients had a confirmed objective response...Disease control was observed in 94% (17/18) of patients...Six patients in the other solid tumor cohort were evaluable for clinical activity. Confirmed partial responses (PRs) were observed in a patient with endometrial cancer and a patient with pancreatic cancer (n=1/1 each); unconfirmed PRs were observed in patients with ovarian cancer and CCA (n=1/1 each).
Trial ID:
